Ferring Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ferring (US): 7 reconciled FDA prescription therapies, $42.9M 2024 CMS Part D & Medicaid spend, and $395 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies7
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$42.9M
2024 Medicare Part D Spend$20.1M
2024 Medicaid Spend$22.9M
California HCAI SB 17 FilingsSpecialty launch notice ($395 intro WAC)